Clinical Trial Detail

NCT ID NCT03255018
Title Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

gray zone lymphoma

diffuse large B-cell lymphoma

Therapies

Pembrolizumab

Age Groups: senior adult child

No variant requirements are available.